Smith & Nephew moves into FTSE big league:
This article was originally published in Clinica
The UK's largest device company Smith & Nephew has been inducted into the blue chip index of UK shares. It took its place in the FTSE 100 list last week. The move will attract institutional investors seeking to track the index. S&N is currently outperforming the FTSE 100. Based on prices a year ago, the index is down 10%, while S&N is up by 50%.
You may also be interested in...
Medical products that do not fully comply with Canadian requirements but are manufactured according to comparable standards are being allowed into the country to deal with COVID-19-related shortages.
A randomized COVID-19 study spanning the whole of the UK could help to bolster the UK’s reputation as a location for future clinical trials. It is also being seen partly as the result of the UK regulator's "decisive action" in fast-tracking trials for potential COVID-19 therapies.
Manufacturers of endoscopic equipment, biofeedback devices and thermometers were among those cited for regulatory violations in US FDA warning letters this week. A total of four device-related enforcement missives were released by the agency.